KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations

Bedard, 2013, Tumour heterogeneity in the clinic, Nature, 501, 355, 10.1038/nature12627

Sensi, 2006, Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma, Oncogene, 25, 3357, 10.1038/sj.onc.1209379

Shackleton, 2009, Heterogeneity in cancer: cancer stem cells versus clonal evolution, Cell, 138, 822, 10.1016/j.cell.2009.08.017

Fukunaga-Kalabis, 2011, From cancer stem cells to tumor maintenance in melanoma, J Invest Dermatol, 131, 1600, 10.1038/jid.2011.159

Quintana, 2008, Efficient tumour formation by single human melanoma cells, Nature, 456, 593, 10.1038/nature07567

Ma, 2011, The role of human aldehyde dehydrogenase in normal and cancer stem cells, Stem Cell Rev, 7, 292, 10.1007/s12015-010-9208-4

Schatton, 2008, Identification of cells initiating human melanomas, Nature, 451, 345, 10.1038/nature06489

Held, 2010, Characterization of melanoma cells capable of propagating tumors from a single cell, Cancer Res, 70, 388, 10.1158/0008-5472.CAN-09-2153

Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027

Vinogradova, 2016, An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells, Nat Chem Biol, 12, 531, 10.1038/nchembio.2085

Gale, 2016, Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance, Oncotarget, 7, 39931, 10.18632/oncotarget.9539

Roesch, 2010, A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth, Cell, 141, 583, 10.1016/j.cell.2010.04.020

Roesch, 2013, Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, Cancer Cell, 23, 811, 10.1016/j.ccr.2013.05.003

Somasundaram, 2012, Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations, Adv Pharmacol, 65, 335, 10.1016/B978-0-12-397927-8.00011-7

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766

Konieczkowski, 2014, A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors, Cancer Discov, 4, 816, 10.1158/2159-8290.CD-13-0424

Manzano, 2016, Resistant mechanisms to BRAF inhibitors in melanoma, Ann Transl Med, 4, 237, 10.21037/atm.2016.06.07

Meeth, 2016, The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations, Pigment Cell Melanoma Res, 29, 590, 10.1111/pcmr.12498

Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454

Obenauf, 2015, Therapy-induced tumour secretomes promote resistance and tumour progression, Nature, 520, 368, 10.1038/nature14336

Halaban, 2010, PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells, Pigment Cell Melanoma Res, 23, 190, 10.1111/j.1755-148X.2010.00685.x

Horton, 2016, Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds, Cell Chem Biol, 23, 769, 10.1016/j.chembiol.2016.06.006

Johansson, 2016, Structural analysis of human KDM5B guides histone demethylase inhibitor development, Nat Chem Biol, 12, 539, 10.1038/nchembio.2087

Liang, 2016, Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies, Bioorg Med Chem Lett, 26, 4036, 10.1016/j.bmcl.2016.06.078

Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc Natl Acad Sci U S A, 105, 3041, 10.1073/pnas.0711741105

Barrett, 2008, The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901, Bioorg Med Chem Lett, 18, 6501, 10.1016/j.bmcl.2008.10.054

Sayegh, 2013, Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen, J Biol Chem, 288, 9408, 10.1074/jbc.M112.419861

Yang, 2007, pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2, Mol Cell, 28, 15, 10.1016/j.molcel.2007.09.010

Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626

Wu, 2018, KDM5 histone demethylases repress immune response via suppression of STING, PLoS Biol, 16, e2006134, 10.1371/journal.pbio.2006134

Kemper, 2014, Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy, Cancer Res, 74, 5937, 10.1158/0008-5472.CAN-14-1174

Menon, 2015, A stress-induced early innate response causes multidrug tolerance in melanoma, Oncogene, 34, 4545, 10.1038/onc.2014.432

Welsh, 2016, Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next?, Eur J Cancer, 62, 76, 10.1016/j.ejca.2016.04.005

Long, 2014, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, 371, 1877, 10.1056/NEJMoa1406037

Fallahi-Sichani, 2017, Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state, Mol Syst Biol, 13, 905, 10.15252/msb.20166796

Richard, 2016, ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors, EMBO Mol Med, 8, 1143, 10.15252/emmm.201505971

Masui, 2013, A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments, Carcinogenesis, 34, 725, 10.1093/carcin/bgt086

Ahn, 2017, The slow cycling phenotype: a growing problem for treatment resistance in melanoma, Mol Cancer Ther, 16, 1002, 10.1158/1535-7163.MCT-16-0535

Haq, 2013, Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF, Cancer Cell, 23, 302, 10.1016/j.ccr.2013.02.003

D'Oto, 2016, Histone demethylases and their roles in cancer epigenetics, J Med Oncol Ther, 1, 34

Blair, 2011, Epigenetic regulation by lysine demethylase 5 (KDM5) enzymes in cancer, Cancers (Basel), 3, 1383, 10.3390/cancers3011383

Zou, 2014, Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes, J Biol Chem, 289, 17620, 10.1074/jbc.M114.570853

Cao, 2014, Histone demethylase RBP2 is critical for breast cancer progression and metastasis, Cell Rep, 6, 868, 10.1016/j.celrep.2014.02.004

Klein, 2014, The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers, Cell Rep, 6, 325, 10.1016/j.celrep.2013.12.021

Albini, 2015, Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity, Connect Tissue Res, 56, 414, 10.3109/03008207.2015.1066780

Marusyk, 2012, Intra-tumour heterogeneity: a looking glass for cancer?, Nat Rev Cancer, 12, 323, 10.1038/nrc3261

Song, 2017, Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation, Cancer Discov, 7, 1248, 10.1158/2159-8290.CD-17-0401

Hu-Lieskovan, 2015, Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma, Sci Transl Med, 7, 279ra41, 10.1126/scitranslmed.aaa4691

Liu, 2015, The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4, Clin Cancer Res, 21, 1639, 10.1158/1078-0432.CCR-14-2339